Correction to: “Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study” - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: “Comparative Cardiovascular Safety of Romosozumab and PTH Analogues in Osteoporosis Management: A Propensity-Score-Matched Analysis”

  • December 17, 2024

Share

  • 1

    The article by Stokar J and Szalat A contained errors in in-text reference citations.

  • 2

    The sixth paragraph of the Discussion section originally included incorrect citations '46-51'.

  • 3

    The erroneous citations were removed, clarifying the text regarding romosozumab's effects on the cardiovascular system.

  • 4

    The corrected sentence states there is no established pathophysiologic pathway linking romosozumab to cardiovascular effects.

  • 5

    The article has been updated online to reflect these corrections.

Original Source(s)

Correction to: “Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study”

  • December 17, 2024

Related Content

Heart Failure is an Independent Risk Factor for Incident Hip, Proximal Humerus, and Wrist Fractures in a High-Risk Older Population

Fracture Risk Associated With Long-Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population-Based Study Using National Claims Data (Système National des Données de Santé)

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.